Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tysabri

Biogen Idec building

Biogen shares peer-reviewed publication of Aduhelm phase 3 data

The trial data was published in The Journal of Prevention of Alzheimer’s Disease

- PMLiVE

Sandoz launches generic oncology treatment in Europe

Lenalidomide can be used to treat patients with haemato-onocology conditions, following recommendations from recent European Society for Medical Oncology (ESMO) guidelines

Biogen Idec building

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis

- PMLiVE

Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US

Biogen and The Alzheimer's Association fear that the approach will unfairly exclude patients from therapies and create further healthcare inequities

- PMLiVE

Biogen pays Ionis $60m for licence to develop ASO for spinal muscular atrophy

The licence is worldwide and exclusive and may include future royalty payments

Biogen Idec building

Biogen’s Aduhelm unlikely to get approval in Europe

In another setback for the controversial Alzheimer’s disease antibody, the EMA’s review committee has voted against recommending the treatment

- PMLiVE

Eisai/Biogen present more data on antibody for Alzheimer’s disease

Phase 2 data shows lecanemab offers a consistent ‘robust’ effect against Alzheimer’s disease, while the phase 3 programme will test plasma biomarkers to identify preclinical disease

Biogen Idec building

Biogen investigating death linked to Aduhelm

The death of a 75-year-old patient taking Biogen’s Aduhelm has raised yet more questions around the recently approved Alzheimer’s therapy

- PMLiVE

Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

The company has started a strategic review of Sandoz as sales drop 20% in ‘challenging’ US market

Biogen Idec building

Biogen’s ALS drug tofersen misses phase 3 endpoint

Following these results, Biogen will now expand its early access programme for tofersen to enable all eligible SOD1-ALS patients worldwide to receive the drug free of charge

- PMLiVE

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis

Sanofi reception

Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis

New long-term data presented at ECTRIMS 2021 reinforces promising safety and efficacy profile

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links